ReviewResearch (Washington, D.C.)2025
Multi-Omics Meets Premalignancy: Paving the Way for Early Prevention of Cancer.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Special Issue "Molecular Biomarkers in Cancers: Advances and Challenges".International journal of molecular sciences · 2026Article
- The Dynamic Alliance of p53 and Metabolism in the Tumor Microenvironment Shapes Tumor Evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Epigenetic Inflammation Supports Tumorigenesis: Activator Protein 1 Drives Stem Cell Memory to Augment Colitis and Cancer.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive understanding of premalignant lesions (PMLs) represents a pivotal opportunity for cancer early detection and interception. Recently, advances in multi-omics technologies and artificial intelligence (AI) methods have provided unprecedented insights into PML-induced tumorigenesis. In this paper, we firstly catalog clinically recognized PMLs across 15 cancer types, emphasizing their epidemiological profiles and malignant transformation potentials. Then, we summarize recent intriguing discoveries and remaining challenges from bulk, single-cell, and spatial omics studies, highlighting how these omics technologies reveal the dynamic molecular, cellular, and spatial evolution from precancerous states to invasive malignancies. We further discuss network-based computational strategies for multi-omics integration and tumorigenesis trajectory inference, with applications of recent deep learning-based AI approaches. Finally, we highlight translational implications for PMLs, including developing high-precision early-diagnosis biomarkers and targeted pharmacological preventive strategies. Collectively, this paper underscores how the convergence of high-resolution multi-omics with sophisticated AI is poised to redefine PML research, enabling pan-cancer exceedingly-early risk stratification and pharmacological prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.